ERAMET (ER7.DE) Fundamental Analysis & Valuation
FRA:ER7 • FR0000131757
Current stock price
51.15 EUR
+0.8 (+1.59%)
Last:
This ER7.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ER7.DE Profitability Analysis
1.1 Basic Checks
- In the past year ER7 has reported negative net income.
- In the past year ER7 has reported a negative cash flow from operations.
- ER7 had positive earnings in 4 of the past 5 years.
- Of the past 5 years ER7 4 years had a positive operating cash flow.
1.2 Ratios
- With a Return On Assets value of -1.58%, ER7 is not doing good in the industry: 69.77% of the companies in the same industry are doing better.
- The Return On Equity of ER7 (-9.29%) is worse than 74.42% of its industry peers.
- ER7's Return On Invested Capital of 0.80% is on the low side compared to the rest of the industry. ER7 is outperformed by 65.12% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for ER7 is in line with the industry average of 9.17%.
- The last Return On Invested Capital (0.80%) for ER7 is well below the 3 year average (7.29%), which needs to be investigated, but indicates that ER7 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.58% | ||
| ROE | -9.29% | ||
| ROIC | 0.8% |
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
1.3 Margins
- ER7's Profit Margin has declined in the last couple of years.
- Looking at the Operating Margin, with a value of 1.91%, ER7 is doing worse than 62.79% of the companies in the same industry.
- ER7's Operating Margin has declined in the last couple of years.
- With an excellent Gross Margin value of 68.15%, ER7 belongs to the best of the industry, outperforming 95.35% of the companies in the same industry.
- ER7's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.91% | ||
| PM (TTM) | N/A | ||
| GM | 68.15% |
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
2. ER7.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ER7 is destroying value.
- ER7 has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, ER7 has more shares outstanding
- The debt/assets ratio for ER7 has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.08, we must say that ER7 is in the distress zone and has some risk of bankruptcy.
- ER7's Altman-Z score of 1.08 is on the low side compared to the rest of the industry. ER7 is outperformed by 83.72% of its industry peers.
- A Debt/Equity ratio of 2.03 is on the high side and indicates that ER7 has dependencies on debt financing.
- ER7's Debt to Equity ratio of 2.03 is on the low side compared to the rest of the industry. ER7 is outperformed by 90.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.08 |
ROIC/WACC0.09
WACC9.21%
2.3 Liquidity
- A Current Ratio of 1.54 indicates that ER7 should not have too much problems paying its short term obligations.
- ER7 has a Current ratio of 1.54. This is in the lower half of the industry: ER7 underperforms 69.77% of its industry peers.
- A Quick Ratio of 1.06 indicates that ER7 should not have too much problems paying its short term obligations.
- ER7 has a Quick ratio (1.06) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.06 |
3. ER7.DE Growth Analysis
3.1 Past
- ER7 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -219.63%.
- Measured over the past years, ER7 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -64.00% on average per year.
- The Revenue has decreased by -6.91% in the past year.
- ER7 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.39% yearly.
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
3.2 Future
- ER7 is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.30% yearly.
- The Revenue is expected to grow by 3.35% on average over the next years.
EPS Next Y-333.81%
EPS Next 2Y-86.68%
EPS Next 3Y-38.88%
EPS Next 5Y-7.3%
Revenue Next Year4.29%
Revenue Next 2Y3.55%
Revenue Next 3Y4.96%
Revenue Next 5Y3.35%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. ER7.DE Valuation Analysis
4.1 Price/Earnings Ratio
- ER7 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ER7 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- ER7's Enterprise Value to EBITDA is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 14.51 |
4.3 Compensation for Growth
- A cheap valuation may be justified as ER7's earnings are expected to decrease with -38.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-86.68%
EPS Next 3Y-38.88%
5. ER7.DE Dividend Analysis
5.1 Amount
- ER7 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ER7.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:ER7 (4/8/2026, 7:00:00 PM)
51.15
+0.8 (+1.59%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)02-18 2026-02-18/amc
Earnings (Next)04-23 2026-04-23
Inst Owners16.96%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.47B
Revenue(TTM)2.88B
Net Income(TTM)-97.00M
Analysts78
Price Target54.36 (6.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP-44.33%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.48%
PT rev (3m)2.3%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.41 | ||
| P/tB | 2.72 | ||
| EV/EBITDA | 14.51 |
EPS(TTM)-3.42
EYN/A
EPS(NY)-6.23
Fwd EYN/A
FCF(TTM)-25.76
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS100.31
BVpS36.3
TBVpS18.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.58% | ||
| ROE | -9.29% | ||
| ROCE | 1.16% | ||
| ROIC | 0.8% | ||
| ROICexc | 0.95% | ||
| ROICexgc | 1.09% | ||
| OM | 1.91% | ||
| PM (TTM) | N/A | ||
| GM | 68.15% | ||
| FCFM | N/A |
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexgc growth 3Y-56.22%
ROICexgc growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 10.29 | ||
| Cap/Depr | 403.31% | ||
| Cap/Sales | 21.11% | ||
| Interest Coverage | 0.34 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 1.08 |
F-Score2
WACC9.21%
ROIC/WACC0.09
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-333.81%
EPS Next 2Y-86.68%
EPS Next 3Y-38.88%
EPS Next 5Y-7.3%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
Revenue Next Year4.29%
Revenue Next 2Y3.55%
Revenue Next 3Y4.96%
Revenue Next 5Y3.35%
EBIT growth 1Y-51.75%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year-4.34%
EBIT Next 3Y26.47%
EBIT Next 5Y19.21%
FCF growth 1Y-850%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.46%
OCF growth 3YN/A
OCF growth 5YN/A
ERAMET / ER7.DE Fundamental Analysis FAQ
What is the fundamental rating for ER7 stock?
ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.
What is the valuation status of ERAMET (ER7.DE) stock?
ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.
How profitable is ERAMET (ER7.DE) stock?
ERAMET (ER7.DE) has a profitability rating of 3 / 10.
How financially healthy is ERAMET?
The financial health rating of ERAMET (ER7.DE) is 2 / 10.
What is the earnings growth outlook for ERAMET?
The Earnings per Share (EPS) of ERAMET (ER7.DE) is expected to decline by -333.81% in the next year.